SMH
TXMD icon

Sanders Morris Harris’s TherapeuticsMD TXMD Stock Holding History

Sanders Morris Harris’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,000
Closed -$75.5K – 247
2023
Q3 		$75.5K Hold
25,000
– – 0.02% 244
2023
Q2 		$103K Sell
25,000
-8,577
-26% -$33.7K 0.02% 242
2023
Q1 		$126K Sell
33,577
-6,816
-17% -$32.7K 0.04% 129
2022
Q4 		$226K Hold
40,393
– – 0.09% 176
2022
Q3 		$268K Buy
+40,393
New +$327K 0.07% 215
2022
Q2 		– Sell
-10,253
Closed -$194K – 308
2022
Q1 		$194K Sell
10,253
-30
-0.3% -$472 0.04% 271
2021
Q4 		$183K Sell
10,283
-60,933
-86% -$1.83M 0.03% 281
2021
Q3 		$2.64M Buy
71,216
+2,400
+3% +$107K 0.48% 40
2021
Q2 		$4.09M Sell
68,816
-1,620
-2% -$98.1K 0.8% 21
2021
Q1 		$4.72M Sell
70,436
-11,866
-14% -$929K 1% 19
2020
Q4 		$4.98M Sell
82,302
-3,631
-4% -$248K 1.13% 16
2020
Q3 		$6.79M Buy
85,933
+11,282
+15% +$899K 1.84% 8
2020
Q2 		$4.67M Sell
74,651
-401
-0.5% -$23.3K 2.27% 11
2020
Q1 		$4K Buy
75,052
+67,632
+911% +$6.71M ﹤0.01% 129
2019
Q4 		$1.81M Sell
7,420
-12,696
-63% -$1.83M 0.41% 66
2019
Q3 		$3.65M Buy
20,116
+12,906
+179% +$1.82M 0.88% 22
2019
Q2 		$937K Sell
7,210
-210
-3% -$37.6K 0.24% 89
2019
Q1 		$1.81M Sell
7,420
-1,350
-15% -$357K 0.88% 25
2018
Q4 		$1.67M Buy
8,770
+170
+2% +$41.5K 0.92% 25
2018
Q3 		$2.82M Sell
8,600
-140
-2% -$42.9K 1.32% 21
2018
Q2 		$2.73M Sell
8,740
-1,290
-13% -$394K 1.26% 21
2018
Q1 		$2.44M Sell
10,030
-400
-4% -$112K 1.02% 24
2017
Q4 		$3.15M Sell
10,430
-446
-4% -$124K 1.33% 18
2017
Q3 		$2.88M Sell
10,876
-346
-3% -$100K 1.23% 22
2017
Q2 		$2.96M Buy
11,222
+1,550
+16% +$388K 1.21% 21
2017
Q1 		$3.48M Sell
9,672
-110
-1% -$34K 1.27% 17
2016
Q4 		$2.82M Sell
9,782
-340
-3% -$105K 1.31% 15
2016
Q3 		$3.45M Buy
10,122
+1,610
+19% +$588K 1.05% 24
2016
Q2 		$3.62M Buy
8,512
+7,092
+499% +$2.92M 0.84% 18
2016
Q1 		$454K Buy
+1,420
New +$484K 0.08% 196

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sanders Morris Harris's TXMD Position: Q4 2023 in Review

Sanders Morris Harris sold out of TherapeuticsMD (TXMD) in Q4 2023, closing a stake of 25,000 shares — an estimated $75.5K sold.

Sanders Morris Harris first reported a position in TXMD in Q1 2016 and held it in 30 quarters. The position peaked at $6.79M in Q3 2020. 39 funds tracked by Wall St. Rank hold TXMD as of Q4 2023.

  • Sanders Morris Harris reported no remaining TherapeuticsMD position as of Q4 2023 after selling out during the quarter.
  • Sanders Morris Harris sold 25,000 TherapeuticsMD shares in Q4 2023, an estimated $75.5K.
  • Sanders Morris Harris first reported a position in TherapeuticsMD in Q1 2016 and held it in 30 quarters.
  • Sanders Morris Harris's TherapeuticsMD position peaked at $6.79M in Q3 2020.
  • 39 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2023.

Based on Sanders Morris Harris's 13F filing for Q4 2023, filed 10 Jan 2024.